Industry Deep-Dive: Non-Invasive Biomarkers for NASH Fibrosis Staging, Disease Monitoring, and Clinical Trial Endpoints
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Non-Alcoholic Steatohepatitis Biomarkers – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis Biomarkers market, including market size, share, demand, industry development status, and forecasts for the next few years.
Core User Pain Point & Solution Direction: Hepatologists, pharmaceutical companies, and clinical researchers face a critical diagnostic challenge: non-alcoholic steatohepatitis (NASH) affects an estimated 5-8% of the global adult population (200-300 million patients), but definitive diagnosis requires invasive liver biopsy (needle core sample, 1-5% complication rate, sampling error, patient reluctance). Patients with NASH are at risk of progressing to cirrhosis (15-20% over 10-15 years) and hepatocellular carcinoma (HCC). Non-alcoholic steatohepatitis biomarkers offer non-invasive alternatives for disease detection, fibrosis staging, progression monitoring, and clinical trial endpoints. Biomarkers categories include hepatic fibrosis biomarkers (ELF, FibroTest, FIB-4, FibroScan), serum biomarkers (CK-18, M30, M65, cytokines, adipokines), oxidative stress biomarkers (8-OHdG, MDA, oxidized LDL), and apoptosis biomarkers (caspase-cleaved cytokeratin-18). For pharmaceutical companies developing NASH drugs (resmetirom approved 2024, other candidates in Phase 2-3), non-invasive biomarkers are essential for patient screening, enrichment, and surrogate endpoints (regulatory acceptance for accelerated approval).
Global Market Size & Growth Trajectory
The global market for Non-Alcoholic Steatohepatitis Biomarkers was estimated to be worth US680millionin2025andisprojectedtoreachUS680millionin2025andisprojectedtoreachUS 1,450 million, growing at a CAGR of 11.4% from 2026 to 2032. Market growth is driven by increasing NASH prevalence (obesity, diabetes epidemic, 30-40% of diabetics have NASH), FDA/EMA acceptance of non-invasive biomarkers for clinical trials (reducing need for paired biopsies), launch of first NASH drug (Rezdiffra, resmetirom, approved March 2024), and development of novel biomarkers (genomic, proteomic, metabolomic, imaging-based).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5983905/non-alcoholic-steatohepatitis-biomarkers
Market Share & Competitive Landscape
The market features a moderately fragmented landscape with diagnostic companies, pharmaceutical partners, and specialized NASH biomarker developers:
- Genfit (France) – Global leader, approximately 15% market share. NIS4 biomarker test (for at-risk NASH), FibroTest franchise.
- Siemens Medical Solutions USA – Approximately 12% share. Enhanced Liver Fibrosis (ELF) test (CE-marked, FDA pending). Strong in lab-based diagnostics.
- Perspectum Diagnostics (UK) – Approximately 10% share. MRI-based imaging biomarkers (LiverMultiScan, cT1 for NASH activity).
- Echosens SA (France) – Approximately 8% share. FibroScan (VCTE, CAP for steatosis and fibrosis). Installed base >5,000 devices globally.
- Quest Diagnostics, LabCorp – US commercial lab leaders, approximately 15% combined. Offer FIB-4, NFS, ELF, proprietary panels.
- AstraZeneca, Pfizer, BMS, Boehringer Ingelheim, Gilead, NGM Biopharmaceuticals – Pharmaceutical companies using biomarkers for drug development (partnerships, in-house assays).
- Prometheus, BioPredictive, One Way Liver, Enterome, Cisbio, Celerion, Xeptagen – Specialist biomarker developers.
The top three (Genfit, Siemens, Perspectum) account for approximately 37% of global market share.
Type Segmentation
- Hepatic Fibrosis Biomarkers (45% share) – Largest segment, 10.5% CAGR. Non-invasive markers of liver fibrosis severity (F0-F4). Includes ELF (PIIINP, HA, TIMP-1, Siemens), FibroTest (α2-macroglobulin, haptoglobin, GGT, apolipoprotein A1, total bilirubin, Genfit), FIB-4 (age, AST, ALT, platelets), FibroScan (VCTE, Echosens). Used for patient screening, risk stratification, and monitoring.
- Serum Biomarkers (28% share) – Fastest-growing segment (12.5% CAGR). Blood-based markers of hepatocyte injury and inflammation. Includes CK-18 fragments (M30, M65, for apoptosis/necrosis), cytokines (IL-6, TNF-α, IL-10), adipokines (leptin, adiponectin). Used in drug development for patient enrichment and pharmacodynamic response.
- Oxidative Stress Biomarkers (10% share) – 8.5% CAGR. Markers of reactive oxygen species damage in NASH pathogenesis. Includes 8-OHdG (DNA oxidation), MDA (lipid peroxidation), protein carbonyls. Research use, not yet clinical.
- Apoptosis Biomarkers (8% share) – 9.0% CAGR. Markers of programmed cell death (caspase-3-cleaved CK-18). Available as ELISA assays (M30, M65). Used in clinical trials.
- Others (9% share) – Genetic biomarkers (PNPLA3, TM6SF2, MBOAT7), microRNA, metabolomics, proteomics, imaging biomarkers (MRI-PDFF, MRE, cT1).
Application Segmentation
- Pharmaceutical Company (60% share) – Largest and fastest-growing segment (13% CAGR). Biomarkers used for patient screening (enrollment criteria), patient enrichment (selecting high-risk patients for trials), pharmacodynamic markers (target engagement), and surrogate endpoints (regulatory submission). Major NASH drug candidates: resmetirom (Madrigal, approved), semaglutide (Novo Nordisk, Phase 3), obeticholic acid (Intercept, re-filing), lanifibranor (Inventiva), efruxifermin (Akero).
- Hospital (30% share) – 9.5% CAGR. Clinical diagnostic use (risk stratification, fibrosis staging, disease monitoring). Primarily ELF, FibroTest, FIB-4, and FibroScan.
- Others (10% share) – Research institutes, academic medical centers, CROs.
Clinical Deep-Dive: Biomarkers vs. Liver Biopsy for NASH Diagnosis
| Parameter | Liver Biopsy (Gold Standard) | ELF (Siemens) | FibroTest (Genfit) | FIB-4 (Free) | FibroScan (Echosens) |
|---|---|---|---|---|---|
| Invasiveness | High (needle biopsy) | Non-invasive (blood) | Non-invasive (blood) | Non-invasive (blood) | Non-invasive (ultrasound) |
| Accuracy for F3-F4 (advanced fibrosis) | Reference | 80-85% (AUROC) | 80-85% | 75-80% | 85-90% |
| Sampling error | 20-30% (inter-observer) | None | None | None | 10-15% (operator-dependent) |
| Cost (US$) | US$ 2,000-5,000 (including pathology) | US$ 200-400 | US$ 150-300 | US$ 20 (lab tests, free) | US$ 100-300 per scan |
| Regulatory acceptance for drug approval | Required (primary endpoint) | Accepted for patient selection, exploratory endpoints | Same | Limited | Same |
| Availability | High (major hospitals) | Moderate (reference labs) | Moderate (Europe, Asia, limited US) | High (calc from routine labs) | Moderate (specialist centers) |
Recent Regulatory Breakthrough (March 2024) – FDA approved Madrigal’s resmetirom (Rezdiffra) for NASH with fibrosis using histology-based endpoints (biopsy required for approval). However, FDA guidance encourages development and qualification of non-invasive biomarkers for future NASH trials. The Liver Forum (public-private partnership) is working to qualify ELF and FibroTest as drug development tools. Qualification would enable accelerated approval using non-invasive biomarkers, avoiding requirement for paired biopsies (reducing trial cost, patient burden).
Typical User Case (Q2 2025) – A Phase 3 NASH clinical trial (double-blind, placebo-controlled, 1,200 patients, 72-week treatment) used ELF (Siemens) as a screening tool to enrich for patients with F2-F3 fibrosis (avoiding F0-F1 who have lower progression risk). ELF score >9.8 (cutoff for significant fibrosis) was required for enrollment. During the trial, ELF was measured at baseline, week 24, 48, 72 as a pharmacodynamic biomarker (treatment response). Result: ELF reduction correlated with histological improvement (biopsy substudy, n=300). The sponsor used ELF data to support regulatory submission (reducing need for on-therapy biopsies).
Exclusive Observation: The NASH Drug Approval Catalyst
The FDA approval of resmetirom (Rezdiffra, Madrigal) in March 2024 is the single most important catalyst for the NASH biomarker market. Key implications:
| Pre-Approval (Before 2024) | Post-Approval (2025 onward) |
|---|---|
| No FDA-approved NASH drugs (off-label only) | First approved therapy (Rezdiffra), more expected 2026-2028 |
| Biomarker market: research use only (low volume) | Clinical monitoring of patients on therapy (high volume) |
| Biomarker testing: clinical trial patients only (tens of thousands) | Biomarker testing: diagnosed NASH patients (millions) |
| Payers: limited coverage for NASH biomarker testing | Payers: coverage for monitoring treatment response |
Market size expansion: Estimated 1-2 million NASH patients in the US with F2-F3 fibrosis eligible for Rezdiffra (annual monitoring recommended). Assuming 1 million patients tested annually (ELF or FibroTest, US200pertest),incrementalbiomarkermarketopportunityUS200pertest),incrementalbiomarkermarketopportunityUS 200 million annually in US alone. Global market larger (Europe, Japan, China).
Industry Segmentation: Diagnostic Testing vs. Pharma R&D Services
The NASH biomarker market spans two distinct business models:
| Segment | NASH Diagnostic Testing | Pharma R&D (Clinical Trial) Biomarkers |
|---|---|---|
| Primary customers | Hospitals, clinics, labs, health systems | Pharmaceutical companies, CROs |
| Revenue model | Fee-for-service (per test, lab-developed tests LDTs) | Service contracts, kit sales, central lab agreements |
| Volume | Potentially high (millions of patients) | Lower (thousands of trial patients) |
| Price per test | US$ 100-400 | US$ 50-200 (volume discount) |
| Regulatory path | LDT (US, changes under LDT rule), CE-IVD (EU) | Research-use only (RUO), not regulated |
| Key players | Quest, LabCorp, Siemens, Genfit, Echosens | Genfit, Perspectum, Cisbio, Celerion |
Cost structure (serum biomarker ELISA kit, CK-18 M30, 96-well plate, US$ 500-1,000):
| Component | Percentage |
|---|---|
| Antibody development and validation | 20-30% |
| Microplate coating and manufacturing | 15-20% |
| Standards and controls (recombinant protein) | 10-15% |
| Regulatory compliance (CE-IVD, LDT) | 10-15% |
| Marketing and distribution | 10-15% |
| Margin (manufacturer) | 30-40% |
Additional Market Dynamics: The NASH biomarker market faces challenges from (1) lack of FDA-qualified non-invasive biomarkers for drug approval (still require biopsy for primary endpoint), (2) variable reimbursement for NASH biomarker testing (CMS coverage limited), (3) competition from imaging biomarkers (MRI-PDFF, MRE, less accessible, higher cost), (4) liver biopsy remains gold standard for diagnosis and staging. However, the combination of NASH drug approval (Rezdiffra, more coming), obesity/diabetes epidemic (driving NASH prevalence), and regulatory efforts to qualify non-invasive biomarkers positions the non-alcoholic steatohepatitis biomarkers market for sustained 10-12% annual growth through 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
